AU4247397A - Method of treating post menopausal diseases, including osteoporosis - Google Patents

Method of treating post menopausal diseases, including osteoporosis

Info

Publication number
AU4247397A
AU4247397A AU42473/97A AU4247397A AU4247397A AU 4247397 A AU4247397 A AU 4247397A AU 42473/97 A AU42473/97 A AU 42473/97A AU 4247397 A AU4247397 A AU 4247397A AU 4247397 A AU4247397 A AU 4247397A
Authority
AU
Australia
Prior art keywords
idoxifene
estrogen
bone
osteoporosis
ere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42473/97A
Other languages
English (en)
Inventor
Jeremy N. Bradbeer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU4247397A publication Critical patent/AU4247397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU42473/97A 1996-09-06 1997-09-03 Method of treating post menopausal diseases, including osteoporosis Abandoned AU4247397A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US60025439 1996-09-06
US5066697P 1997-06-24 1997-06-24
US60050666 1997-06-24
PCT/US1997/015474 WO1998009519A1 (fr) 1996-09-06 1997-09-03 Methode destinee a traiter des maladies post-menopausiques, dont l'osteoporose

Publications (1)

Publication Number Publication Date
AU4247397A true AU4247397A (en) 1998-03-26

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
AU42473/97A Abandoned AU4247397A (en) 1996-09-06 1997-09-03 Method of treating post menopausal diseases, including osteoporosis
AU44097/97A Abandoned AU4409797A (en) 1996-09-06 1997-09-03 Novel methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU44097/97A Abandoned AU4409797A (en) 1996-09-06 1997-09-03 Novel methods

Country Status (16)

Country Link
EP (2) EP0927029A4 (fr)
JP (2) JP2002515046A (fr)
KR (2) KR20000068472A (fr)
CN (2) CN1236299A (fr)
AR (1) AR008155A1 (fr)
AU (2) AU4247397A (fr)
BR (2) BR9711676A (fr)
CA (2) CA2264943A1 (fr)
CO (2) CO4920218A1 (fr)
CZ (1) CZ76699A3 (fr)
IL (1) IL128645A0 (fr)
NO (2) NO991097L (fr)
PL (2) PL332278A1 (fr)
TR (2) TR199900504T2 (fr)
TW (1) TW411273B (fr)
WO (2) WO1998009519A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034608A1 (fr) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methodes therapeutiques ou prophylactiques a l'encontre de symptomes menopausiques
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260066B1 (fr) * 1986-09-11 1990-05-09 National Research Development Corporation Dérivés du tamoxifène
DE69316633T2 (de) * 1992-09-15 1998-05-20 Merrell Dow Pharma Nichtmetabolisierbare clomiphene-analoge zur behandlung von tamoxifen-resistenten tumoren
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
KR20000068473A (ko) 2000-11-25
NO991096L (no) 1999-03-05
CA2264943A1 (fr) 1998-03-12
PL332038A1 (en) 1999-08-16
NO991097D0 (no) 1999-03-05
AR008155A1 (es) 1999-12-09
TW411273B (en) 2000-11-11
BR9711676A (pt) 1999-08-24
NO991097L (no) 1999-03-05
JP2002515046A (ja) 2002-05-21
TR199900506T2 (xx) 1999-07-21
WO1998009519A1 (fr) 1998-03-12
NO991096D0 (no) 1999-03-05
IL128645A0 (en) 2000-01-31
JP2002515047A (ja) 2002-05-21
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
EP0929216A4 (fr) 2001-04-04
EP0927029A1 (fr) 1999-07-07
CA2264775A1 (fr) 1998-03-12
CZ76699A3 (cs) 1999-08-11
CO4920218A1 (es) 2000-05-29
EP0929216A1 (fr) 1999-07-21
CN1236299A (zh) 1999-11-24
PL332278A1 (en) 1999-08-30
TR199900504T2 (xx) 1999-06-21
EP0927029A4 (fr) 2001-06-13
KR20000068472A (ko) 2000-11-25
CO5070658A1 (es) 2001-08-28
CN1236313A (zh) 1999-11-24
WO1998009619A1 (fr) 1998-03-12

Similar Documents

Publication Publication Date Title
Ke et al. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model
EP1438957B1 (fr) Raloxifène destinée au traitement de l'ostéoporose post-ménopause
Mitlak et al. Selective estrogen receptor modulators: a look ahead
KR101141763B1 (ko) 체중 증가의 치료 및/또는 억제에 사용하는 약학 조성물
KR100278946B1 (ko) 혈청 콜레스테롤을 저하시키는데 유용한 벤조티오펜
Evans et al. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia
HUT72638A (en) Pharmaceutical compositions containing benzotiophene derivative for inhibiting bone loss and for lowering serum cholesterol and process for its preparation
US4970237A (en) Use of clomiphene to increase bone mass in premenopausal women
AU4247397A (en) Method of treating post menopausal diseases, including osteoporosis
US4820736A (en) Use of clomiphene to predict fertility in a human female
EP1140047B1 (fr) Hormonotherapie du cancer du sein associee a un traitement au tamoxifene et aux dibenzofurannes polychlores alkyles
MXPA99002213A (en) Method of treating post menopausal diseases, including osteoporosis
EP0747056B1 (fr) Diminuer la perte osseuse par des combinaisons d'anti-estrogènes
WO1999000019A1 (fr) Procedes de traitement des symptomes de la vaginite atrophique et du comportement sexuel modifie chez des femmes postmenopausees
Goulding et al. Effects of clomiphene and tamoxifen in vivo on the bone-resorbing effects of parathyroid hormone and of high oral doses of calcitriol (1, 25 (OH) 2D3) in rats with intact ovarian function consuming low calcium diet
PL186085B1 (pl) Stosowanie antyestrogenów do kontroli płodności męskiej
Lamarca The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis
AL-GANZOURY et al. Effect of estrogen agonist antagonist on bone mineral density in postmenopausal breast cancer
Whitehead Effects of Oral, Percutaneous and Transdermal Oestrogens on Postmenopausal Bone
Tau et al. Marked recovery from axial osteopenia in children with liver transplantation
WO1998049896A1 (fr) Methode de traitement de symptomes vasomoteurs
MXPA99002214A (en) Novel methods
WO1999000018A1 (fr) Methodes de traitement des symptomes de troubles de la memoire, de la concentration et de la cognition chez la femme menauposee

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted